Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation
| العنوان: | Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation |
|---|---|
| المؤلفون: | Sachiko Seo, Minoo Battiwalla, Witold B. Rybka, Mahmoud Aljurf, Amir Steinberg, John R. Wingard, Olle Ringdén, Ami J. Shah, Neel S. Bhatt, Siddhartha Ganguly, Navneet S. Majhail, Jean A. Yared, Zachariah DeFilipp, Gerhard C. Hildebrandt, Saurabh Chhabra, Richard F. Olsson, Peiman Hematti, Melhem Solh, Biljana Horn, Helen Leather, Ruta Brazauskas, Bronwen E. Shaw, David Buchbinder, Biju George, Kristin Page, Amer Beitinjaneh, Mary E.D. Flowers, David A. Jacobsohn, Heather R. Tecca, Usama Gergis, Vaibhav Agrawal, Sherif M. Badawy, Hélène Schoemans, Robert Peter Gale, Betty K. Hamilton, Ibrahim Ahmed, David I. Marks, Tamila L. Kindwall-Keller, Raquel M. Schears, Jane L. Liesveld, Juan Gea-Banacloche, Bipin N. Savani, Andrew C. Dietz, Maxim Norkin, Hillard M. Lazarus, Peter J. Shaw, Nandita Khera, Kimberly A. Kasow, Rammurti T. Kamble, Marcie L. Riches, Yoshihiro Inamoto, Harry C. Schouten |
| المساهمون: | RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Hematologie (9) |
| المصدر: | Biology of Blood and Marrow Transplantation, 25(2), 362-368. Elsevier Science |
| بيانات النشر: | Elsevier Science, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Male, Myeloid, Time Factors, medicine.medical_treatment, Hematopoietic stem cell transplantation, Pediatrics, IMMUNE RECONSTITUTION, 0302 clinical medicine, Late fatal infection, Medicine, Cumulative incidence, Child, Cause of death, Hematology, Hematopoietic cell transplantation, Incidence, Age Factors, Hematopoietic Stem Cell Transplantation, Middle Aged, Allografts, Leukemia, Leukemia, Myeloid, Acute, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Child, Preschool, Female, Infection, Life Sciences & Biomedicine, Adult, medicine.medical_specialty, Adolescent, Immunology, Infections, Article, 03 medical and health sciences, Internal medicine, Humans, Adults, Aged, Immunosuppression Therapy, Transplantation, Science & Technology, business.industry, Infant, Newborn, Infant, medicine.disease, BONE-MARROW-TRANSPLANTATION, Confidence interval, Chronic Disease, business, 030215 immunology |
| الوصف: | We analyzed late fatal infections (LFIs) in allogeneic stem cell transplantation (HCT) recipients reported to the Center for International Blood and Marrow Transplant Research. We analyzed the incidence, infection types, and risk factors contributing to LFI in 10,336 adult and 5088 pediatric subjects surviving for ≥2 years after first HCT without relapse. Among 2245 adult and 377 pediatric patients who died, infections were a primary or contributory cause of death in 687 (31%) and 110 (29%), respectively. At 12 years post-HCT, the cumulative incidence of LFIs was 6.4% (95% confidence interval [CI], 5.8% to 7.0%) in adults, compared with 1.8% (95% CI, 1.4% to 2.3%) in pediatric subjects; P < .001). In adults, the 2 most significant risks for developing LFI were increasing age (20 to 39, 40 to 54, and ≥55 years versus 18 to 19 years) with hazard ratios (HRs) of 3.12 (95% CI, 1.33 to 7.32), 3.86 (95% CI, 1.66 to 8.95), and 5.49 (95% CI, 2.32 to 12.99) and a history of chronic graft-versus-host disease GVHD (cGVHD) with ongoing immunosuppression at 2 years post-HCT compared with no history of GVHD with (HR, 3.87; 95% CI, 2.59 to 5.78). In pediatric subjects, the 3 most significant risks for developing LFI were a history of cGVHD with ongoing immunosuppression (HR, 9.49; 95% CI, 4.39 to 20.51) or without ongoing immunosuppression (HR, 2.7; 95% CI, 1.05 to 7.43) at 2 years post-HCT compared with no history of GVHD, diagnosis of inherited abnormalities of erythrocyte function compared with diagnosis of acute myelogenous leukemia (HR, 2.30; 95% CI, 1.19 to 4.42), and age >10 years (HR, 1.92; 95% CI, 1.15 to 3.2). This study emphasizes the importance of continued vigilance for late infections after HCT and institution of support strategies aimed at decreasing the risk of cGVHD. ispartof: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION vol:25 issue:2 pages:362-368 ispartof: location:United States status: published |
| وصف الملف: | Print-Electronic |
| اللغة: | English |
| تدمد: | 1523-6536 1083-8791 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11d89b635c0a27f35128ccc8ca34be71Test https://doi.org/10.1016/j.bbmt.2018.09.031Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....11d89b635c0a27f35128ccc8ca34be71 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15236536 10838791 |
|---|